Hansa Biopharma AB (publ) (HNSBF) to Release Quarterly Earnings on Wednesday

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) is expected to be posting its resultson Wednesday, July 22nd. Analysts expect the company to announce earnings of ($0.0346) per share and revenue of $5.17 million for the quarter.

Hansa Biopharma AB (publ) Price Performance

Shares of Hansa Biopharma AB (publ) stock opened at $2.90 on Wednesday. The firm has a fifty day moving average price of $2.90 and a 200 day moving average price of $2.90. Hansa Biopharma AB has a 1 year low of $2.90 and a 1 year high of $2.90.

Wall Street Analyst Weigh In

Separately, Danske began coverage on Hansa Biopharma AB (publ) in a research note on Tuesday, June 16th. They set a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Hansa Biopharma AB (publ) presently has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.